Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people worldwide — and only around 5% have an approved treatment. As global attention grows, including the WHO’s upcoming 10-year Global Action Plan, it is important to understand how regulation, HTA, and pricing policies across the UK, EU, and US influence the development of orphan medicines and access for patients.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
Professor Graham Cookson responds to President Donald Trump’s Executive Order on drug prices published earlier this week.
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
Today marks Rare Disease Day 2025. This time last year we published an Article entitled “ Why do we care about rare?”, summarising the origins of…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.
A Spotlight on Haemophilia Therapies
3 October 2024
Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.
The Cost of Drug Shortages
16 September 2024
Across the globe, drug shortages are becoming increasingly common.